RxDoctor Payments Data

Larissa Luu, MD

Family Medicine · Santa Ana, CANPI 1750940714

Payments from drug & device makers

$4,649in general payments, 2019–2025

Across 283 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$751
  • Novo Nordisk$655
  • Pfizer$478
  • Lilly USA, LLC$324
  • GSK$309
  • AstraZeneca$252
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,649100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,649 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$55,433
Medicare patients
177
Services billed
1,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin69$74,443
MounjaroTirzepatide51$54,059
OzempicSemaglutide32$35,844
VraylarCariprazine Hcl18$29,787
TrulicityDulaglutide20$26,395
JanuviaSitagliptin Phosphate17$25,339
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$24,593
RybelsusSemaglutide11$24,526
FarxigaDapagliflozin Propanediol14$15,151
XareltoRivaroxaban17$14,317
EliquisApixaban12$13,881
MyrbetriqMirabegron15$13,511
Varenicline Tartrate15$2,692
Albuterol Sulfate HfaAlbuterol Sulfate60$2,413
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$324$80,45471 claims
Boehringer IngelheimJardiance$126$74,44369 claims
Novo NordiskOzempic, Rybelsus$655$60,37043 claims
AbbVieVraylar, Synthroid$751$30,90033 claims
MerckJanuvia$51$25,33917 claims
GSKTrelegy Ellipta$309$24,59333 claims
AstraZenecaFarxiga$252$15,15114 claims
PfizerEliquis$478$13,88112 claims
Astellas Pharma US IncMyrbetriq$107$13,51115 claims
Almatica Pharma LLCSertraline Hcl$49$76078 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →